Pall Corporation Strengthens Leadership in Proteomics Market with New Enchant Life Sciences Kits

Strategic Insights -

Pall Corporation has introduced three new protein purification kits, the Enchant Life Sciences Kit for Albumin Depletion and the two Enchant Life Sciences Kits for IgG Purification, designed to remove abundant proteins from human and animal-derived serum or plasma samples. This innovation supports the increasing demand for proteomics technologies, which are projected to expand to $367.7 million by 2009. The Enchant Life Sciences Kits provide researchers with advanced options for uncovering low abundant biomarkers, crucial for developing new therapeutics.

Key Takeaways:

  • The Enchant Life Sciences Kits are the first entries in Pall Corporation's extended line of products for the proteomics market, supporting the company's business strategy to establish leadership in high-growth areas of drug discovery and protein purification.
  • The kits remove abundant proteins from human and animal-derived serum or plasma samples, providing the critical first step in isolating new drug targets.
  • The kits are designed to support the shift from genomics to proteomics as the key technology to transform information into pharmaceutical production.
  • The Enchant Life Sciences Kits are reusable gravity-based columns with high binding capacities for the effective purification or depletion of IgG.
  • The kits can be used for purifying a variety of immunoglobulin molecules and isotypes from a broad range of species.
  • The total proteomics market is expected to reach $3.3 billion in 2006, and Pall Corporation aims to provide purification solutions across all stages of drug development.
  • The company estimates that proteomics has the potential to decrease spending per new chemical compound by approximately 30% and decrease the time investment by two years.
  • Pall Corporation's business is organized around two broad markets: Life Sciences and Industrial, with total revenues of $1.6 billion.
  • The company has operations in more than 30 countries, with headquarters in East Hills, New York.

Statistics:

  • The Enchant Life Sciences market is projected to expand to $367.7 million by 2009.
  • The total proteomics market is expected to reach $3.3 billion in 2006.
  • Proteomics has the potential to decrease spending per new chemical compound by approximately 30% (from an average cost of $500 to $750 million per compound).
  • Proteomics can decrease the time investment by two years (from an average of 10 to 12 years from discovery to market).
  • Total revenues for Pall Corporation are $1.6 billion.

Sources:

  • "Pall Corporation Strengthens Leadership in Proteomics Market with New Enchant Life Sciences Kits"

+ Pall Corporation (NYSE: PLL)

+ BUSINESS WIRE (East Hills, N.Y.--(BUSINESS WIRE)--Aug. 9, 2004--)

  • Pall Corporation's website: www.pall.com
  • ASIA PULSE 12-08 1935